• Mashup Score: 0

    n in the same country. In this study, we aimed to evaluate the clinical features and disease course of BD using cluster analysis in Van province, Eastern Turkey. Methods This study was carried out in a tertiary referral center in Van province, by reviewing medical records. Seven disease manifestations were included to the cluster analysis as follows: mucocutaneous findings (oral ulcer, genital ulcer, erythema nodosum–like lesions, pseudofolliculitis), uveitis, superficial thrombophlebitis, musculoskeletal involvement, gastrointestinal system involvement, vascular involvement, and parenchymal central nervous system involvement. Results We identified 467 patients. After the exclusion of 6 patients who had missing data and 17 patients who did not live in Van, 444 patients (59.2% male) included into the study. Meeting the International Study Group and the International Criteria for Behçet Disease criteria were 91.6% and 96%, respectively, and 91.3% (n = 379/415) of these patients met both

    Tweet Tweets with this article
    • Clinical features and disease course of #Behçet Disease using cluster analysis. https://t.co/LdIWbKJ9fV

  • Mashup Score: 4

    In this Review, the authors discuss vascular involvement in Behçet syndrome and how the unusual pathogenesis involving an impaired immune-inflammatory response influences the treatment approach, which differs from that of other vasculitides.

    Tweet Tweets with this article
    • #FebruaryIssue | Vascular involvement is common in #Behçet syndrome. The pathogenesis and clinical aspects of #vascular Behçet syndrome, and their implications for therapeutic management, are discussed in this #Review. https://t.co/QTOFhKweDA https://t.co/d5uRFZ1I8M

  • Mashup Score: 0

    Objectives The endoplasmic reticulum aminopeptidase ( ERAP1 ) haplotype Hap10 encodes for a variant allotype of the endoplasmic reticulum (ER)-resident peptide-trimming aminopeptidase ERAP1 with low enzymatic activity. This haplotype recessively confers the highest risk for Behçet’s diseases (BD) currently known, but only in carriers of HLA-B*51 , the classical risk factor for the disease. The…

    Tweet Tweets with this article
    • Check out the novel finding about genetic basis of #Behçet disease: ▶️ ERAP1-Hap10/HLA-B51 skews frequencies and phenotypes of antigen-experienced versus naïve cytotoxic CD8 Tcells ▶️ Knock out ERAP1 alters HLA-I peptidome towards hyporreactivity 🔗 https://t.co/xgmDVRauHR https://t.co/JBEX5ZiOh8

  • Mashup Score: 0

    Objective To assess apremilast’s impact on patient quality of life (QoL) in active Behçet’s syndrome and correlations between improvement in patients’ QoL and efficacy measures in the phase 3 RELIEF study. Methods QoL measures included Behçet’s Disease QoL (BDQoL), 36-Item Short-Form Health Survey V.2 (SF-36v2) Physical/Mental Component Summary (PCS/MCS) and eight subscale scores, focusing on…

    Tweet Tweets with this article
    • What is the effect of #apremilast in #behçet syndrome? Check out findings from phase III RELIEF study ▶️ improvement in quality of life (SF-36) & physical functioning ▶️ these paralleled reduction in number of ulcers and disease activity (BDAF) 🔗 https://t.co/SxFvUeOLAW https://t.co/uXDRN0Un9N

  • Mashup Score: 0

    Behçet’s syndrome (BS) was first described by Hulusi Behçet in 1931, as a definite clinical entity, the ‘triple symptom complex’, based on…

    Tweet Tweets with this article
    • This review sheds insight into the rare inflammatory disease of the blood vessels known as #Behçet’s syndrome (BS). The authors share clinical manifestations of the mucosa, skin, nervous system, and #musculoskeletal system in BS. https://t.co/jUbnjrBvCz #rarediseaseday https://t.co/jU98r6Trqm